Articles

Merck's Cornerstone Cancer Drug at ASCO: Key Insights

At ASCO, Merck showcased its cornerstone cancer drug, highlighting its potential impact on treatment paradigms and market positioning. This article delves into key insights and implications for pharmaceutical stakeholders.

Ebola at the World Cup: What We Should Really Worry About

This article discusses the potential public health implications of Ebola at the World Cup, focusing on the more pressing health threats that may arise during large events.

Oura's Entry into Cuffless Blood Pressure Monitoring

Oura has entered the cuffless blood pressure monitoring space with its new rings. This article explores the implications for the pharmaceutical sector.

STAT+: Insights on Pancreatic Cancer Ahead of ASCO 2026

As ASCO 2026 approaches, pancreatic cancer remains a focal point for pharmaceutical advancements. This article explores key developments and their implications for the industry.

AbbVie Secures FDA Approval for ImmunoGen's Elahere in Rare Blood Cancer

AbbVie has received FDA approval for Elahere, a significant advancement in the treatment of rare blood cancers. This article explores the implications for pharmaceutical teams and investors.

STAT+: ASCO Preview: Key Insights for Pharma Leaders

This article previews the upcoming ASCO meeting, highlighting critical insights and implications for pharmaceutical professionals. Stay informed on the latest developments in cancer research.

Latest Developments on Ebola, Hepatitis B, and Long Covid

This article covers the most recent developments in Ebola, hepatitis B, and long Covid, highlighting their implications for the pharmaceutical industry.

Hepatitis B Drug Developments and Lilly's Obesity Drug Returns

This article discusses the latest advancements in hepatitis B drug development and the implications of CVS reinstating Lilly's obesity drug on formularies.

Blood Pressure Tech Market Surge Post-FDA Oversight Changes

The FDA's recent relaxation of oversight on blood pressure wearables has led to a surge in market entries. This article explores the implications for pharmaceutical teams.

Pharma Leaders Advocate for Japan's R&D Investment

Pharma leaders recently met with Japan's Prime Minister Takaichi to discuss strategies for maintaining the country's R&D leadership. This article outlines key takeaways and implications for the pharmaceutical industry.

Trump's Pharma Deals Under Scrutiny: Insights and Implications

This article analyzes the recent scrutiny of Trump's pharmaceutical deals, focusing on their implications for business development teams and investors. Key insights and competitive impacts are discussed.

FDA Alert: Infectious Diseases Drug News Roundup 2026

This article provides a comprehensive roundup of the latest FDA alerts regarding infectious diseases drug trials in 2026, highlighting key implications for stakeholders.

AstraZeneca's Imfinzi Secures Second Bladder Cancer Approval

AstraZeneca's Imfinzi has gained a second approval for bladder cancer treatment, marking a significant milestone in its development. This article explores the implications for the pharmaceutical landscape.

Research Progress and Development Strategies of Antibody-Oligonucleotide Conjugates

This article provides an in-depth analysis of the recent progress in antibody-oligonucleotide conjugates, focusing on clinical trials and their strategic implications for the pharmaceutical industry.

Ebola Outbreak Response: U.S. Fortification Strategies

As the Ebola outbreak escalates in Central Africa, the U.S. implements stringent measures. This article examines the implications for the pharmaceutical sector.

GSK and Ionis Present Promising Hepatitis B Drug Data

GSK and Ionis have unveiled significant data on their hepatitis B drug, presenting a potential functional cure. This development could reshape treatment strategies in the pharmaceutical industry.

FDA PreCheck Pilot Program Launches: A New Era for Clinical Trials

The FDA's PreCheck Pilot Program aims to streamline clinical trial approvals, offering significant implications for pharmaceutical companies and investors. This article analyzes the program's launch and its potential impact on the industry.

ASCO 2026: What to Expect from the Upcoming Event

ASCO 2026 is set to be a pivotal event for the pharma industry. Here’s what B2B readers should know ahead of the conference.

New Data on Experimental Hepatitis B Treatment: A Functional Cure

Recent findings indicate that an experimental treatment for hepatitis B has achieved a functional cure in nearly one in five patients, signaling potential shifts in the market.

Trump's Drug-Pricing Deals: New Product Launches on the Horizon

As new pharmaceutical products are set to launch, Trump's drug-pricing deals face critical scrutiny. This article delves into the implications for business development teams and investors.